Last reviewed · How we verify

parecoxib, valdecoxib, etoricoxib

Asker & Baerum Hospital · FDA-approved active Small molecule

parecoxib, valdecoxib, etoricoxib is a COX-2 selective inhibitor (coxib) Small molecule drug developed by Asker & Baerum Hospital. It is currently FDA-approved for Acute postoperative pain, Rheumatoid arthritis, Osteoarthritis.

These drugs selectively inhibit cyclooxygenase-2 (COX-2) to reduce inflammation and pain without significantly affecting COX-1-mediated gastric protection.

These drugs selectively inhibit cyclooxygenase-2 (COX-2) to reduce inflammation and pain without significantly affecting COX-1-mediated gastric protection. Used for Acute postoperative pain, Rheumatoid arthritis, Osteoarthritis.

At a glance

Generic nameparecoxib, valdecoxib, etoricoxib
SponsorAsker & Baerum Hospital
Drug classCOX-2 selective inhibitor (coxib)
TargetCOX-2 (cyclooxygenase-2)
ModalitySmall molecule
Therapeutic areaPain Management / Rheumatology
PhaseFDA-approved

Mechanism of action

COX-2 selective inhibitors block the enzyme responsible for producing prostaglandins that drive inflammation, fever, and pain signaling. By sparing COX-1, they aim to reduce gastrointestinal toxicity compared to non-selective NSAIDs, though cardiovascular risks remain a concern with this class.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about parecoxib, valdecoxib, etoricoxib

What is parecoxib, valdecoxib, etoricoxib?

parecoxib, valdecoxib, etoricoxib is a COX-2 selective inhibitor (coxib) drug developed by Asker & Baerum Hospital, indicated for Acute postoperative pain, Rheumatoid arthritis, Osteoarthritis.

How does parecoxib, valdecoxib, etoricoxib work?

These drugs selectively inhibit cyclooxygenase-2 (COX-2) to reduce inflammation and pain without significantly affecting COX-1-mediated gastric protection.

What is parecoxib, valdecoxib, etoricoxib used for?

parecoxib, valdecoxib, etoricoxib is indicated for Acute postoperative pain, Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.

Who makes parecoxib, valdecoxib, etoricoxib?

parecoxib, valdecoxib, etoricoxib is developed and marketed by Asker & Baerum Hospital (see full Asker & Baerum Hospital pipeline at /company/asker-baerum-hospital).

What drug class is parecoxib, valdecoxib, etoricoxib in?

parecoxib, valdecoxib, etoricoxib belongs to the COX-2 selective inhibitor (coxib) class. See all COX-2 selective inhibitor (coxib) drugs at /class/cox-2-selective-inhibitor-coxib.

What development phase is parecoxib, valdecoxib, etoricoxib in?

parecoxib, valdecoxib, etoricoxib is FDA-approved (marketed).

What are the side effects of parecoxib, valdecoxib, etoricoxib?

Common side effects of parecoxib, valdecoxib, etoricoxib include Hypertension, Edema, Dyspepsia, Cardiovascular events (myocardial infarction, stroke), Headache.

What does parecoxib, valdecoxib, etoricoxib target?

parecoxib, valdecoxib, etoricoxib targets COX-2 (cyclooxygenase-2) and is a COX-2 selective inhibitor (coxib).

Related